Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 31;114(4):1208–1217. doi: 10.1111/cas.15728

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Microvasculature with abundant endothelial fenestration (EFs) on VHL null clear cell renal cell carcinoma (ccRCC) might be vascular endothelial growth factor (VEGF)‐dependent capillaries and sensitive to anti‐VEGF therapy. (A) The graph shows a significant reduction of EFs in VHL ^−/− pRC3 xenografts by the bevacizumab treatment. (B) Effects of bevacizumab treatment on microvessel density. Significant reduction was observed in VHL ^−/− pRC3 xenografts. HPF, high power filed. (C) Antitumor effects of bevacizumab in ccRCC tumors established in nude mice. Each time point represents the mean ± SE of the fold of tumor volume in each group. Statistically significant differences were observed in the tumor size of VHL ^−/− pRC3 xenografts between the bevacizumab treatment mice and controls. NS, not significant.